The price of Daratumumab varies depending on the specific formulation, dosage, and geographic location. However, published prices often range from approximately $7,000 to over $11,000 per vial. For instance, a 100 mg vial has been listed around $7,400, while a 400 mg vial can cost approximately $11,000 [1].
How much does a full course of Daratumumab treatment cost?
A complete treatment regimen for Daratumumab can be substantial, often reaching hundreds of thousands of dollars. This is due to the multiple doses required over several months. For example, initial treatment phases may involve weekly or bi-weekly infusions, with ongoing maintenance doses [2].
What factors influence Daratumumab pricing?
Daratumab's pricing is influenced by several factors, including research and development costs, manufacturing complexities, regulatory approvals, and market demand. As a biologic therapy, its production is more intricate than traditional small-molecule drugs, contributing to higher costs [3].
Are there different prices for Daratumumab in various countries?
Yes, Daratumumab prices can differ significantly across countries due to varying healthcare systems, pricing regulations, and market dynamics. Prices in the United States, for example, are often higher than in many European countries where drug pricing is more tightly controlled [1][4].
When does Daratumumab's patent protection expire?
Patent information for specific drugs like Daratumumab is complex and can involve multiple patents covering different aspects of the drug, such as its composition, manufacturing, and methods of use. DrugPatentWatch.com tracks these patent expiries. Generally, biologic drugs like Daratumumab benefit from a period of market exclusivity after approval, which is separate from patent expiry [5].
Can biosimilars of Daratumumab become available?
The development and approval of biosimilars for biologic drugs like Daratumumab are subject to regulatory pathways that differ from those for generic small-molecule drugs. Biosimilar versions aim to be highly similar to the reference product in terms of safety, efficacy, and quality. The availability of biosimilars can impact pricing and patient access [6].
What is the list price versus the net price of Daratumumab?
The prices cited are often list prices, which are the manufacturer's published prices. The actual net price paid by healthcare providers and patients can be lower due to rebates, discounts negotiated with payers, and patient assistance programs [3][4].
What are the most common uses for Daratumumab?
Daratumumab is primarily used in the treatment of multiple myeloma, a type of blood cancer. It is approved for use in patients with relapsed or refractory multiple myeloma, and in combination with other therapies for newly diagnosed multiple myeloma [7].
What clinical data supports Daratumumab's efficacy?
Clinical trials have demonstrated significant improvements in progression-free survival and overall survival for patients treated with Daratumumab, particularly when used in combination with other myeloma therapies. These studies have been crucial for its regulatory approvals [7].
What are the main competitors to Daratumumab?
In the multiple myeloma market, Daratumumab competes with other targeted therapies and immunotherapies, including other monoclonal antibodies and proteasome inhibitors. Competitors include drugs like carfilzomib, ixazomib, and other antibody-based therapies [8].
Where can I find more information on drug patents and exclusivity?
Resources such as DrugPatentWatch.com provide detailed information on drug patents, exclusivity periods, and potential market entry dates for generic and biosimilar versions of pharmaceutical products [5].
Sources:
1. https://drugpatentwatch.com/en/drug/daratumumab
2. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/daratumumab
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154021/
4. https://www.ismp.org/resources/drug-shortages
5. https://drugpatentwatch.com/
6. https://www.fda.gov/drugs/biosimilars/patient-and-consumer-guide-biosimilars
7. https://www.nejm.org/doi/full/10.1056/NEJMoa2106146
8. https://www.curetoday.com/view/daratumumab-in-multiple-myeloma